Mark Agulnik, MD
Medical Oncology · Los Angeles, CANPI 1164448734
Payments from drug & device makers
Across 517 payments — averaging $9701.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$1.2M
- Exelixis Inc.$826K
- Novartis$784K
- Otsuka Pharmaceutical Co., Ltd.$487K
- PTC Therapeutics, Inc.$441K
- Aadi Bioscience, Inc.$269K
- plus $1M from 25 others
What the payments were for
- Consulting fees$86,50329%
- Speaking & faculty fees$188,00362%
- Travel & lodging$20,2947%
- Food & beverage$7,9953%
- Gifts$2120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 147 | $1,188,864 |
| Exelixis Inc. | 7 | $826,369 |
| Novartis | 3 | $784,371 |
| Otsuka Pharmaceutical Co., Ltd. | 8 | $487,113 |
| PTC Therapeutics, Inc. | 14 | $440,658 |
| Aadi Bioscience, Inc. | 23 | $268,665 |
| Bayer | 78 | $232,663 |
| Boehringer Ingelheim | 28 | $213,158 |
| GSK | 10 | $152,762 |
| Merck | 53 | $148,983 |
| Epizyme, Inc. | 14 | $62,250 |
| Eisai Inc. | 6 | $61,143 |
| Blueprint Medicines Corporation | 12 | $52,636 |
| Regeneron Healthcare Solutions, Inc. | 24 | $25,692 |
| Daiichi Sankyo Inc. | 27 | $17,492 |
| Springworks Therapeutics, Inc. | 19 | $14,696 |
| E.r. Squibb & Sons, L.L.C. | 10 | $11,872 |
| Sanofi | 8 | $10,547 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $7,848 |
| AstraZeneca | 2 | $3,471 |
| Boehringer Ingelheim International GmbH | 1 | $1,113 |
| Eli Lilly | 1 | $1,050 |
| Lantheus Medical Imaging, Inc. | 1 | $800 |
| Foundation Medicine, Inc. | 2 | $700 |
| Galvanize Therapeutics, Inc | 1 | $198 |
| Tempus AI, Inc | 5 | $137 |
| Johnson & Johnson | 3 | $83 |
| Sobi, Inc | 2 | $62 |
| Beone Medicines USA, Inc. | 2 | $41 |
| Astellas Pharma US Inc | 1 | $29 |
| Tactile Systems Technology Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vitrakvi$82,839
- QINLOCK$75,476
- LIBTAYO$33,423
- Turalio$16,999
- OGSIVEO$14,454
- OPDIVO$11,612
- FYARRO$11,215
- AYVAKIT$5,740
- VIMSELTINIB$4,569
- LYNPARZA$3,450
- ROMVIMZA$3,351
- Stivarga$2,328
- FOUNDATIONONE LIQUID$700
- FOUNDATIONFOCUS$700
- FOUNDATIONONE CDX$700
- FOUNDATIONONE HEME$700
- FOUNDATIONONE$700
- ALIYA SYSTEM$198
- Cabometyx$135
- TGCT$117
How this compares
$5,015,483 in reported general payments places this provider in the 90th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 55 | $58,267 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Los Angeles
- Sarmad SadeghiLos Angeles$26.1M
- Heinz-Josef LenzLos Angeles$11.6M
- Anthony El-KhoueiryLos Angeles$10.5M
- Stephen LiuLos Angeles$8M
- David QuinnLos Angeles$4M
- Daphne StewartLos Angeles$4M
- Patricia YoungLos Angeles$3.1M
- David TranLos Angeles$3.1M
- Syma IqbalLos Angeles$1.9M
- Afsaneh BarziLos Angeles$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.